Lewy Body Dementia Market is segmented By Diagnosis (Clinical Diagnosis, Biomarker-based Diagnosis), By Medication (Cholinesterase Inhibitors, Antipsy....
Market Size in USD
CAGR7.5%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.5% |
Market Concentration | High |
Major Players | EIP Pharma Inc., Cognition Therapeutics, Eisai Inc., Eli Lilly and Company, Athira Pharma |
The Global Lewy Body Dementia Market is estimated to be valued at USD 1.25 Bn in 2024 and is expected to reach USD 2.01 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031. Lewy body dementia is a common form of progressive dementia that causes a decline in thinking, reasoning and independent function over time. It can vary in its severity and rate of progression.
The market is expected to grow at a steady rate during the forecast period. Rising elderly population worldwide and increasing prevalence of Lewy body dementia are the key factors driving the market. In addition, approval and launch of new drugs and growing number of research activities for developing innovative treatment therapies are further expected to boost the market growth over the coming years.